Acute oncology care: a narrative review of the acute management of neutropenic sepsis and immune-related toxicities of checkpoint inhibitors.
AffiliationUniversity Hospital of South Manchester, Manchester, UK
MetadataShow full item record
AbstractCancer care has become increasingly specialized and advances in therapy have resulted in a larger number of patients receiving care. There has been a significant increase in the number of patients presenting with cancer related emergencies including treatment toxicities and those directly related to the malignancy. Suspected neutropenic sepsis is an acute medical emergency and empirical antibiotic therapy should be administered immediately. The goal of empirical therapy is to cover the most likely pathogens that will cause life-threatening infections in neutropenic patients. Patients with febrile neutropenia are a heterogeneous group with only a minority of treated patients developing significant medical complications. Outpatient management of low risk febrile neutropenia patients identified by the MASCC score is a safe and effective strategy. Immunotherapy with "checkpoint inhibitors" has significantly improved outcomes for patients with metastatic melanoma and evidence of benefit in a wide range of malignancies is developing. Despite these clinical benefits a number of immune related adverse events have been recognised which can affect virtually all organ systems and are potentially fatal. The timing of the onset of the adverse events is dependent on the organ system affected and unlike anti-neoplastic therapy can be delayed significantly after initiation or completion of therapy. The field of Acute Oncology is changing rapidly. Alongside, the traditional challenge of neutropenic sepsis there are many emerging toxicities. Further research into the optimal management, strategies and pathways of acutely unwell patients with cancer is required.
CitationAcute oncology care: a narrative review of the acute management of neutropenic sepsis and immune-related toxicities of checkpoint inhibitors. 2017, Eur J Intern Med
JournalEuropean Journal of Internal Medicine
- Neutropenic sepsis: a potentially life-threatening complication of chemotherapy.
- Authors: Ford A, Marshall E
- Issue date: 2014 Oct
- Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.
- Authors: Ahn S, Rice TW, Yeung SJ, Cooksley T
- Issue date: 2018 May
- Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO).
- Authors: Kochanek M, Schalk E, von Bergwelt-Baildon M, Beutel G, Buchheidt D, Hentrich M, Henze L, Kiehl M, Liebregts T, von Lilienfeld-Toal M, Classen A, Mellinghoff S, Penack O, Piepel C, Böll B
- Issue date: 2019 May
- Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice.
- Authors: Kumar P, Bajpai J, Shetty N, Medekar A, Kurkure PA, Ghadyalpatil N, Gupta S, Noronha V, Kanujia A, Parikh P, Banavali SD
- Issue date: 2014 Oct-Dec
- Problem-based review: Immune-mediated complications of 'Checkpoint Inhibitors' for the Acute Physician.
- Authors: Webb P, Rice TW, Cooksley T
- Issue date: 2017